The IMPACT study suggested that carriers of MSH2 and MSH6 pathogenic variants have a higher incidence of prostate cancer compared with non-carrier controls, and therefore prostate-specific antigen (PSA) screening may be useful in Lynch syndrome [9]. This evidence concerns the gene MSH2 and prostate cancer.